Journal
BRAIN RESEARCH
Volume 1207, Issue -, Pages 182-192Publisher
ELSEVIER
DOI: 10.1016/j.brainres.2008.02.043
Keywords
deferoxamine; hypoxia-inducible factor-1; ischemic prevention; neural stem cell; transplantation
Categories
Ask authors/readers for more resources
Hypoxia-inducible factor-1 (HIF-1) plays important roles in the prevention of cerebral ischemia. Deferoxamine (DFX), an iron chelator stabilizes the HIF-1 alpha and activates target genes involved in compensation for ischemia. in this study, we are to investigate whether HIF-1 alpha can be stabilized in human neural stem cells (NSCs) by DFX, and pre-transplantation of NSCs with HIF-1 alpha stabilization can induce prolonged ischemic tolerance. In the DFX-treated NSCs, the HIF-1 alpha protein expression was increased about 100-fold time-dependently, and subsequent transcriptional activation (VEGF, BDNF and CXCR4) was also observed. To test an ability to induce ischemic prevention in vivo, DFX-treated NSCs or naive NSCs were transplanted in the striatum of adult rats. Seven days following the transplantation, focal cerebral ischemia was done. Infarct volumes were reduced in both NSCs-transplanted groups, compared with ischemia-only, but more reduced in DFX-treated NSCs group. The protective effects of NSCs were ablated when HIF-1 alpha was silenced. HIF-1 alpha protein levels were increased in both NSCs-transplanted groups, but more increased in DFX-treated NSCs group. RT-PCR analysis manifested a downregulation of mRNA expression of TNF-alpha, IL-6 and MMP-9 in both NSCs groups, but further decrease in DFX-treated NSCs group. These findings provide evidence that HIF-1 alpha stabilization in human NSCs can be achieved effectively by DFX, and HIF-1 alpha-stabilized NSCs protect against ischemia in a preventive mode. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available